TP53 and neoplasm: All Ad-p53 treated target lesion responders by RECIST 1.1 criteria had received Ad-p53 doses greater than 7 × 1010 viral particles/cm3 tumor and there was a statistically significant difference in tumor responses between patients treated with greater than 7 × 1010 viral particles/cm3 compared to patients treated at lower Ad-p53 doses.